MarketPulse

Alzheimer's disease

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Acumen Pharma to Unveil 2025 Results as Alzheimer's Drug Advances

Acumen Pharmaceuticals will report full-year 2025 financial results on March 26, 2026, as its lead Alzheimer's candidate progresses through Phase 2 trials.
HALOABOSPhase 2 clinical trialfinancial results
GlobeNewswire Inc.GlobeNewswire Inc.··Inmune Bio Inc.

INmune Bio's Alzheimer's Trial Wins Spotlight as Model for Inflammation-Targeting Approach

INmune Bio's XPro trial gains recognition at AD/PD 2026 for innovative biomarker-enriched Alzheimer's approach, securing FDA approval to advance to Phase 2b/3 registrational studies.
INMBclinical trialAlzheimer's disease
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Acumen Pharma to Present Alzheimer's Drug Data at Stifel CNS Forum

Acumen Pharmaceuticals to present Alzheimer's drug candidate sabirnetug at Stifel CNS Forum on March 18, 2026, as Phase 2 trials advance.
HALOABOSPhase 2 clinical trialmonoclonal antibody
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Alzheimer's Therapeutics Market Set to Exceed $6B by 2026 Amid Rising Investment

Alzheimer's therapeutics market projected to exceed $6B by 2026 driven by rising disease prevalence and increased pharma investment in disease-modifying treatments.
ABBVLLYNVORHHBYBIIBmarket growthAlzheimer's disease